Bendamustine: Rescue of an Effective Antineoplastic Agent From the Mid-Twentieth Century

Seminars in Hematology

Volumn 48, Issue SUPPL. 1, 2011, Pages

  Leoni, Lorenzo M ^a  

^a Actus Advisory   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CARMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; MELPHALAN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER RELAPSE; CHRONIC LYMPHATIC LEUKEMIA; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FOLLICULAR LYMPHOMA; HISTORY OF MEDICINE; HUMAN; HYPERBILIRUBINEMIA; HYPERURICEMIA; INFECTION; LEUKOPENIA; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PNEUMONIA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; HEMATOLOGIC NEOPLASMS; HUMANS; NITROGEN MUSTARD COMPOUNDS;

EID: 79955434981     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2011.03.002     Document Type: Article

References (34)

1. Ozegowski W., Krebs D. IMET 3393, γ-[1-methyl-5-bis(β-chloroethyl)-amino-benzimidazolyl-2]-butyric acid hydrochloride, a new cytostatic agent from among the series of benzimidazole mustard compounds. Zbl Pharma 1971, 110:1013-1019. [in German].
2. Cheson B.D., Rummel M.J. Bendamustine: rebirth of an old drug. J Clin Oncol 2009, 27:1492-1501.
3. Leoni L.M., Bailey B., Reifert J., et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008, 14:309-317.
4. Strumberg D., Harstrick A., Doll K., Hoffmann B., Seeber S. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 1996, 7:415-421.
5. Konstantinov S.M., Kostovski A., Topashka-Ancheva M., Genova M., Berger M.R. Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines. J Cancer Res Clin Oncol 2002, 128:271-278.
6. Fleck O., Nielsen O. DNA repair. J Cell Sci 2004, 117:515-517.
7. Sarkaria J.N., Kitange G.J., James C.D., et al. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res 2008, 14:2900-2908.
8. Paik J., Duncan T., Lindahl T., Sedgwick B. Sensitization of human carcinoma cells to alkylating agents by small interfering RNA suppression of 3-alkyladenine-DNA glycosylase. Cancer Res 2005, 65:10472-10477.
9. Teichert J., Baumann F., Chao Q., et al. Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. Cancer Chemother Pharmacol 2007, 59:759-770.
10. Teichert J., Sohr R., Baumann F., et al. Synthesis and characterization of some new phase II metabolites of the alkylator bendamustine and their identification in human bile, urine, and plasma from patients with cholangiocarcinoma. Drug Metab Dispos 2005, 33:984-992.
11. Gandhi V. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin Oncol 2002, 29(Suppl 13):4-11.
12. Cheson B.D., Wendtner C.M., Pieper A., et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 2010, 10:21-27.
13. Byrd J.C., Peterson B.L., Morrison V.A., et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003, 101:6-14.
14. Bergmann M.A., Goebeler M.E., Herold M., et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica 2005, 90:1357-1364.
15. Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. J Cancer Res Clin Oncol 2002, 128:603-609.
16. Friedberg J.W., Cohen P., Chen L., et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008, 26:204-210.
17. Heider A., Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anticancer Drugs 2001, 12:725-729.
18. Kahl B.S., Bartlett N.L., Leonard J.P., et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer 2010, 116:106-114.
19. Kath R., Blumenstengel K., Fricke H.J., Hoffken K. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 2001, 127:48-54.
20. Knauf W.U., Lissichkov T., Aldaoud A., et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009, 27:4378-4384.
21. Knop S., Straka C., Haen M., Schwedes R., Hebart H., Einsele H. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005, 90:1287-1288.
22. Lissitchkov T., Arnaudov G., Peytchev D., Merkle K. Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol 2006, 132:99-104.
23. Niederle N., Balleisen L., Heit W. Bendamustine vs fludarabine as second-line treatment for patients with chronic lymphocytic leukemia-first interim results of a randomized study. Ann Oncol 2008, 19(suppl 4). Abstract 379.
24. Pönisch W., Mitrou P.S., Merkle K., et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone-a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006, 132:205-212.
25. Ogura M., Uchida T., Taniwaki M., et al. Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 2010, 101:2054-2058.
26. Owen J.S., Melhem M., Passarell J.A., D'Andrea D., Darwish M., Kahl B. Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 2010, 66:1039-1049.
27. Fischer K., Stilgenbauer S., Schweighofer C. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicenter phase II trial of the German CLL Study Group (GCLLSG). Blood 2008, 112. Abstract 330.
28. Cheson B.D., Friedberg J., Kahl B. Bendamustine produces durable responses with an acceptable long-term safety profile in patients with rituximab-refractory non-Hodgkin's lymphoma. Blood 2009, 114. Abstract 268.
29. Robinson K.S., Williams M.E., van der Jagt R.H., et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:4473-4479.
30. Rummel M.J., Al-Batran S.E., Kim S.Z., et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:3383-3389.
31. Rummel M., Niederle N., Maschmeyer G. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular indolent and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2009, 114. Abstract 405.
32. Leoni L.M., Niemeyer C.C., Kerfoot C. In vitro and ex vivo activity of SDX-105 (bendamustine) in drug-resistant lymphoma cells. Proc Am Assoc Cancer Res 2004, 45. Abstract 1215.
33. Aivado M., Schulte K., Henze L., Burger J., Finke J., Haas R. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. Semin Oncol 2002, 29(Suppl 13):19-22.
34. Weidmann E., Kim S.Z., Rost A., et al. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2002, 13:1285-1289.